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Purpose:  Leukotriene receptor antagonists (LTRAs) are used to treat aspirin-intolerant asthma (AIA); however, the protective effects of long-term 
LTRA administration against aspirin-induced bronchospasm have not been evaluated.  Objectives:  We investigated the efficacy of a 12-week 
treatment with a LTRA in protecting against aspirin-induced asthma in AIA patients.  Methods:  Fifty-two adult patients with AIA underwent an as-
pirin challenge test just before administration of montelukast (10 mg/day) and just after 12 weeks of treatment. The protective effect was assessed 
as the disappearance of aspirin-induced bronchospasm after 12 weeks of treatment. The results were compared according to the patients’ clinical 
and physiological parameters.  Results:  The decline in FEV1 following aspirin challenge was significantly reduced from 28.6±1.9% to 10.2±1.7% 
(P=0.0001) after 12 weeks of montelukast treatment. However, 14 subjects (30%) still showed a positive response (>15% decline in FEV1) to aspirin 
challenge. Grouping the subjects into good and poor responders according to post-treatment responses revealed that the pretreatment aspirin-in-
duced FEV1 decline was significantly greater in the poor responders and that the triggering dose of aspirin and the induction time for a positive re-
sponse were lower and shorter, respectively, in the poor responders. Histories of aspirin hypersensitivity and sinusitis were more prevalent among 
the poor responders than among the good responders.  Conclusions:  Twelve weeks of treatment with montelukast protected against aspirin-in-
duced bronchospasm in 70% of the AIA cases. A poor response was associated with more severe aspirin-induced bronchospasms before treatment 
and a history of aspirin hypersensitivity or sinusitis.  Clinical implications:  A severe response to aspirin challenge may be a predictor of poor re-
sponsiveness to leukotriene antagonist treatment.
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INTRODUCTION
Aspirin-induced asthma (AIA) refers to the development of 
bronchoconstriction in asthmatic individuals following the in-
gestion of aspirin or other nonsteroidal anti-inflammatory 
drugs (NSAIDs).
1 Although AIA affects only 5-10% of adults 
with asthma,
2 aspirin hypersensitivity has attracted a great deal 
of attention because of its association with increased asthma 
severity and possible remodeling of both the upper and lower 
airways.
3 A two-compartment model has been proposed.
4 The 
overproduction of cysteinyl leukotrienes (CysLTs) has been 
demonstrated in the airways and circulation of asthmatic pa-
tients intolerant to aspirin.
5,6 In addition, compared with aspi-
rin-tolerant asthma (ATA) patients, AIA patients had greater 
airway hyperresponsiveness on inhalation challenge with 
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CysLTs.
7 These data suggest the presence of augmented target-
organ responsiveness to CysLTs. CysLTs exert their biological 
actions by binding to two types of G protein-coupled receptors, 
i.e., cysteinyl leukotriene receptor 1 (CYSLTR1), which is sensi-
tive to the asthma drugs montelukast (MLK), zafirlukast, and 
pranlukast,
8,9 and CYSLTR2.
10
Clinical trials in adults and children with asthma have estab-
lished the efficacy of MLK,
11,12 although significant inter-patient 
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variability in the response to MLK has been observed in both 
children and adults with asthma.
13,14 In a group of relatively se-
vere AIA patients, MLK administered as an add-on therapy 
markedly reduced asthma symptoms and improved lung func-
tion.
15 Variable results have been reported regarding the protec-
tive effects of leukotriene receptor blockers against aspirin-in-
duced bronchoconstriction.
16-19 However, these studies used 
small study populations of fewer than 10-15 subjects and short 
periods of drug administration (about 1 week). Recently, a rela-
tively long-term trial used nasal provocation tests with lysine-
aspirin to evaluate the protective effects of 10 mg of MLK daily 
for 4 weeks in 36 nonsmokers with AIA; this regimen substan-
tially improved nasal function and nasal responses to aspirin in 
the AIA patients,
20 albeit with wide variation among the pa-
tients. To our knowledge, no previous studies have investigated 
the protection by MLK against aspirin-induced bronchospasm 
in a relatively long-term trial (12 weeks) using an oral provoca-
tion test. Therefore, we examined the protective effect of treat-
ment for 12 weeks with the recommended dose of a CYSLTR 
antagonist (MLK 10 mg/day) against aspirin-induced broncho-
spasm in AIA patients; and identified the clinical or physiologi-
cal factors that determined the outcome of CYSLTR antagonist 
treatment in these patients.
MATERIALS AND METHODS
Study design
The study subjects were recruited from among asthmatic pa-
tients who had been followed regularly at the outpatient clinics 
of Soonchunhyang University Bucheon and Seoul Hospital, 
Korea and who had stable mild to moderate asthma according 
to the GINA guidelines.
21 A clinical history, including age at on-
set, duration of asthma, history of smoking, and history of aspi-
rin hypersensitivity, was obtained for each subject before entry 
into the study. Chest posterior-anterior radiography, skin prick 
testing for allergens, counting of blood eosinophils, determina-
tion of the IgE level, and testing for bronchodilator response af-
ter inhalation of two puffs of aerosolized albuterol (100 µg) and 
airway hyperresponsiveness (PC20 methacholine) were con-
ducted within 4 weeks before study. Skin prick tests were per-
formed with 24 common aeroallergens (Bencard Co. Ltd., 
Brentford, UK), and atopy was defined as one or more positive 
reactions (>3 mm in diameter). Total IgE was measured using a 
UniCAP system (Pharmacia Diagnostics, Uppsala, Sweden). 
The body mass index (BMI) and the presence of sinusitis and 
nasal polyps were determined.
The oral aspirin provocation test was performed with increas-
ing doses (10 to 650 mg) of aspirin (Astrix; Mayne Pharma Ltd., 
Melbourne, Australia), using a slightly modified version of the 
method described previously.
22,23 Changes in FEV1 were moni-
tored for 5 hours after the last dose of aspirin challenge or until 
the subject complained of intolerable dyspnea. The rate of FEV1 
decline following aspirin challenge was calculated as the pre-
challenge FEV1 minus the lowest post-challenge FEV1 divided 
by the pre-challenge FEV1×100. Subjects with a greater than 
20% decline in FEV1 without extrabronchial symptoms, or with 
a greater than 15% decline with extrabronchial nasal or skin 
manifestations, were defined as showing a positive response
22,23 
and were enrolled in the study. After informed written consent 
was obtained, MLK (10 mg) was administered daily to the sub-
jects for 12 weeks, and then the second aspirin challenge test 
was performed. During the study period, patients were asked to 
continue taking any inhaled steroids at the preciously pre-
scribed dosage and to use short-acting bronchodilators as 
needed. The response to MLK was defined as good or poor 
when the aspirin-induced rate of FEV1 decline in the second 
aspirin challenge was <15% or >15%, respectively.
Subjects
A total of 53 subjects who had been diagnosed with AIA were 
enrolled in the study. The clinical symptoms and physical char-
acteristics of the subjects were compatible with asthma. Each 
patient showed airway reversibility, as documented by a posi-
tive bronchodilator response of a >15% increase in FEV1 and/
or airway hyperreactivity to <10 mg/mL methacholine. The ex-
clusion criteria included duration of asthma of <1 year, acutely 
exacerbated asthma within 4 weeks, history of brittle asthma, 
atopy to pollens, parenchymal lung disease apparent on simple 
chest radiography, and previous use of leukotriene antagonists. 
This study was approved by the Ethics Committee of Soonc-
hunhyang University Hospital, and informed written consent 
was obtained from all study subjects prior to enrollment.
Statistical analysis
The data were double-entered into SPSS (ver. 10.0; SPSS Inc, 
Chicago, IL, USA). The Wilcoxon signed ranks sum test was ap-
plied to compare the effects of MLK according to clinical pa-
rameters. Comparisons of continuous variables for good and 
poor responders with asthma were made using the indepen-
dent samples t-test. Differences in the proportions of patient 
populations were analyzed by the c
2 test, with Fisher’s exact test 
when low expected cell counts were encountered. In all analy-
ses, P<0.05 was taken to indicate statistical significance.
RESULTS
Clinical parameters of the study subjects
This prospective trial involved 52 patients with AIA. All sub-
jects received 10 mg of MLK before sleep each night for 12 
weeks. Six subjects were excluded from the analysis: 2 suffered 
acute exacerbation following self-withdrawal of inhaled steroid, 
and four took less than 90% of the scheduled doses of MLK. The 
compliance rates for medication in the other 46 subjects were 
above 90%. Thirty-two subjects showed an aspirin-induced de-Allergy Asthma Immunol Res. 2010 January;2(1):48-54.  doi: 10.4168/aair.2010.2.1.48
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cline in FEV1 of less than 15% after the second aspirin chal-
lenge (good responders); the decline was greater than 15% in 
14 subjects (poor responders, Fig. 1). The mean compliance 
rate was not significantly different between the good and poor 
responders (95.5±1.2% and 96.2±1.1%, respectively; P>0.05). 
Thirty subjects had mild asthma and 16 had moderate asthma. 
Thirty subjects used inhaled steroids. No side effects of MLK 
treatment that interrupted medication were observed during 
the study period. The clinical parameters of the subjects are 
summarized in Table 1.
Comparison of clinical parameters according to the response to 
MLK
Thirty-two (70%) of the 46 patients who completed the 12-
week treatment showed a good response to MLK, with a de-
cline in FEV1 of less than 15% on aspirin challenge after treat-
ment (Table 1). The mean age at diagnosis of aspirin hypersen-
sitivity and the asthma duration were similar between the good 
and poor responders. The proportions of patients with mild 
and moderate asthma just before MLK treatment were also 
comparable between the two groups. The dosages of inhaled 
steroid were equivalent between the good and poor responders 
(626±124 µg and 669±102 µg beclomethasone/day, respective-
ly; P>0.05). Theophylline was used in combination with inhaled 
steroid by 3 patients from each group. Nine poor responders 
and seven good responders used short-acting inhaled bron-
chodilators as needed.
The percentage of patients with a history of aspirin hypersen-
sitivity was higher in the poor responders compared with the 
good responders (57.1 versus 18.8%, respectively; P=0.014), and 
the poor responders had a higher incidence of rhinosinusitis 
(92.9 versus 65.6%, respectively; P=0.052). There were no signif-
icant differences between the two groups with respect to the ra-
tio of current to ex-smokers, the frequencies of atopy and nasal 
polyps, BMI, total IgE, and blood eosinophils (Table 1). There 
was no difference in FEV1 or FVC between before and after 
treatment with MLK (Table 1).
Comparison of physiological parameters according to  
the response to MLK
Before treatment with MLK, the decline in FEV1 following as-
pirin challenge ranged from 15% to 62% (28.6±1.9%). After 12 
weeks of treatment, the decline in FEV1 following aspirin chal-
lenge was significantly less, -9% to 51% (10.2±1.7%; P=0.0001; 
Table 2 and Fig. 1A). Nevertheless, 14 subjects (30%) still 
showed a positive response to aspirin challenge (>15% decline 
in FEV1) after 12 weeks of treatment with MLK (poor respond-
ers), and two subjects showed an increased FEV1 after 12 
weeks of treatment, compared with before treatment (Fig. 1A). 
The decline in FEV1 following aspirin challenge before treat-
Fig. 1.  Change of % fall of FEV1 ratio following aspirin challenge after treatment with Montelukast. Aspirin induced - % fall in FEV1 were measured before and af-
ter treatment with daily 10 mg of Montelukast for 12 wk.
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ment was different between the good and poor responders 
(24.7±1.8% versus 37.6±3.8%, respectively; P=0.005) (Table 2). 
Before MLK treatment, the cumulative dose of aspirin required 
to induce bronchospasm was much lower in the poor respond-
ers than in the good responders (860.0±95.3 mg versus 1021.0± 
40.8 mg, respectively; P<0.05), and the induction time for a pos-
itive response was also shorter in the poor responder group 
(Table 2). The pretreatment PC20 methacholine value was sig-
nificantly lower in the good responders than in the poor re-
sponders (2.95±1.2 mg/mL versus 7.54±3.1 mg/mL, respective-
ly; P=0.036). The FEV1 did not differ between the two groups 
(P<0.05) before treatment, and the FEV1 (%, predicted) and 
Table 1.  Clinical profiles of the study subjects
Clinical profiles Total Good responder Poor responder
No. of subjects 46 32 14
Age of diagnosis (mean (range)) 47.2 (18-71) 47.9 (18-71) 45.7 (26-67)
Sex (male/female) 14/32 11/21 3/11
Onset age of asthma (yr) (mean (range)) 41.6 (1-68) 42.3 (1-68) 40.1 (16-66)
Duration of asthma (yr) (range) 5.7 (1-28) 5.6 (1-23) 5.7 (1-28)
Asthma severity before treatment with MLK
3) (mild/moderate) 30/16 21/11 9/5
Use of inhaled steroid 30 (65%) 16 (50%) 10 (71%)
Dosage (µg equivalent to beclomethasone/day) 646±113 626±124 669±102
CS/ES/NS
1) 6/6/34 3/5/24 3/1/10
History of AH
2) 14 (30.4%) 6 (18.8%)
† 8 (57.1%)
History of sinusitis 34 (73.9%) 21 (65.6%)
† 13 (92.9%)
Nasal polyp 33 (71.7%) 17 (73.9%) 11 (78.6%)
BMI (Kg/m
2) (range) 24.2 (18.9-32.9) 24.0 (18.9-30.1) 24.5 (19.0-32.9)
Total IgE (IU/mL) 342.9±73.6 372.9±100.9 274.2±74.7
Atopy (%) 27 (58.7) 21 (65.6) 6 (42.9)
Blood eosinophil (%) 7.6±0.8 8.1±1.1 6.4±1.0
Blood eosinophil count (/µL) 545.6±72.6 561.9±96.9 508.4±92.3
Good responder: ASA induced rate of FEV1 decline after treatment with MLK <15%; Poor responder: ASA induced rate of FEV1 decline after treatment with MLK 
>15%; 
†P value <0.05 vs. poor responder.
1) CS/ES/NS, current smoker/ex-smoker/never-smoker; 
2) AH, aspirin hypersensitivity; 
3) Montelukast treatment, 10 mg/day for 3 mo.
Table 2.  Physiologic parameters of the study subjects
Clinical profiles Total Good responder Poor responder
No. of subjects 46 32 14
Before treatment with MLK
FEV1 (%, predicted) 85.1±2.6 82.4±3.1 91.1±4.9
FVC (%, predicted) 87.2±2.6 86.2±2.3 92.8±4.0
PC20, methacholine (mg/mL) 4.1±1.2 2.95±1.2
† 7.54±3.1
ASA induced rate of FEV1 decline (%) 28.6±1.9 24.7±1.8
‡ 37.6±3.8
ASA cumulative dose of challenge (mg) 972.0±41.4 1,021.0±40.8
† 860.0±95.3
Time of positive response 1.6±0.2 1.9±0.2
† 1.0±0.3
After treatment with MLK
1)
FEV1 (%, predicted) 86.4±2.8 87.4±3.3 84.0±5.0
FVC (%, predicted) 88.6±2.5 86.2±2.5 86.9±4.1
ASA induced rate of FEV1 decline 10.2±1.7 3.4±0.9
‡ 25.5±2.6
ASA cumulative dose of challenge 968.8±42.1 1,037±34.9
‡ 811.8±104.0
Time of positive response 1.8±0.2 2.0±0.2 1.5±0.3
Good responder: ASA induced rate of FEV1 decline after treatment with MLK <15%; Poor responder: ASA induced rate of FEV1 decline after treatment with MLK 
>15%; 
†P value <0.05 vs. poor responder; 
‡P value <0.01 vs. poor responder.
1) Montelukast treatment, 10 mg/day for 3 mo.Allergy Asthma Immunol Res. 2010 January;2(1):48-54.  doi: 10.4168/aair.2010.2.1.48
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FVC (%, predicted) were comparable in each group.
After 12 weeks of treatment with MLK, the decline in FEV1 fol-
lowing aspirin challenge was significantly lower in the good re-
sponders than in the poor responders (3.4±0.9% versus 25.5± 
2.6%, respectively; P=0.0001). The cumulative dose of aspirin 
needed to induce bronchospasm was still lower in the poor re-
sponders compared with the good responders (811.8±104.0 mg 
versus 1037.0±34.9 mg, respectively; P<0.05). FEV1 (%, predict-
ed) and FVC (%, predicted) at the second challenge were com-
parable in the two groups.
DISCUSSION
CYSLTR1 is a G protein-coupled receptor with seven trans-
membrane domains. It is expressed primarily in airway smooth 
muscle, eosinophils, macrophages, and splenocytes. Sousa et 
al. reported that the number of cells expressing CYSLTR1 in the 
nasal mucosa is significantly higher in cases of AIA with chron-
ic rhinosinusitis than in aspirin-tolerant patients, suggesting 
that CYSLTR1 overexpression is crucial to the pathogenesis of 
aspirin hypersensitivity.
4 CysLTs bind to CYSLTR1 with a rank 
order of potency of LTD4>LTC4>LTE4,
24 and the receptor is an-
tagonized selectively by currently available leukotriene modifi-
ers, including MLK, pranlukast, and zafirlukast.
8,9
Although CYSLTR1 antagonists are expected to exert protec-
tive effects against aspirin-induced asthma in AIA patients, the 
significance and extent of the effect have remained controver-
sial and inconclusive because of the small study populations 
and short-term treatment regimens used in previous stud-
ies.
16-18 Our findings provide further insight into the protective 
effect of a CYSLTR1 antagonist against oral aspirin challenge. In 
AIA patients, the decline in FEV1 following aspirin challenge 
was markedly decreased after 12 weeks of treatment with MLK, 
as compared with the values before treatment (Fig. 1A). Never-
theless, 30% of the patients still showed a positive response to 
aspirin challenge after 12 weeks of MLK treatment, and in two 
patients, the response to aspirin challenge was greater after 
MLK treatment than before. This variability in responses has 
also been observed in a previous study using a sample size of 
fewer than six subjects.
16 Although our study population was 
significantly larger, it was still far from being large enough to 
justify any definitive clinical conclusions. A double-blind, pla-
cebo-controlled crossover study with the leukotriene pathway 
inhibitor zileuton in 40 patients showed a distinct reduction of 
aspirin-induced bronchospasm.
25 On the other hand, unex-
pected increases in the frequency of positive aspirin challenge 
responses in AIA patients taking leukotriene modifier drugs 
have been reported.
18,26
We defined the good responder and poor responder groups 
according to the presence of aspirin-induced bronchospasm 
after MLK treatment (Fig. 1B). In the present study, poor re-
sponsiveness was associated with aspirin hypersensitivity and 
sinusitis, but not with age, gender, asthma duration, or the ratio 
of current to ex-smokers. These data indicate that compared 
with the good responders, the poor responders might have had 
a greater response to ingested aspirin. The prevalence of nasal 
polyps (about 70%) was similar between the two groups, sug-
gesting that the nasal reaction to aspirin ingestion was similar 
between the groups. One possible alternative explanation for 
the variability in the response is a difference in awareness 
among the subjects regarding bronchospasm following aspirin 
ingestion. To clarify this, we compared the physiological pa-
rameters of basal pulmonary function and aspirin-induced 
bronchospasm.
Before treatment with MLK, the percentage fall in FEV1 fol-
lowing aspirin challenge was greater in the poor responders 
than in the good responders. In addition, the triggering dose 
and induction time for aspirin-induced bronchospasm were 
greater and shorter, respectively, in the poor responders. These 
observations clearly indicate a greater response to aspirin in-
gestion in the bronchial trees of the poor responders compared 
with the good responders. It is not known whether the nasal re-
activity was similar to bronchial reactivity, because we did not 
measure nasal physiology at the same time. Even after treat-
ment with MLK for 12 weeks, the triggering dose for aspirin-in-
duced bronchospasm was not changed from that determined 
prior to treatment. This suggests that the increased responsive-
ness of the bronchial tree to aspirin challenge did not change in 
the poor responders.
The variability in the protective effect of MLK may be attribut-
able to differences in the severity of asthma, as aspirin sensitivi-
ty occurs more frequently in cases of severe asthma.
3 In the 
present study, lung function did not differ between the good 
and poor responders before or after MLK treatment, suggesting 
that asthma severity may not be associated with the protective 
effects of MLK against aspirin-induced bronchospasm. Howev-
er, we did not include subjects with severe asthma, as they 
could not be subjected to aspirin challenge. During the study 
period, the patients were asked to continue taking inhaled ste-
roids at the previous dosage to avoid inhaled steroid withdraw-
al-associated exacerbation of asthma. One major limitation of 
the present study was the absence of placebo controls to docu-
ment the known “spontaneous” variability of asthma, as the 
spontaneous variability of aspirin hypersensitivity has not been 
reported.
To search for clinical parameters identifying a poor responder, 
we compared the BMI, skin test reactivity, total IgE, and periph-
eral blood eosinophil count between the two groups. None of 
these parameters were associated with the response. Eosino-
phils and mast cells show marked infiltration into the bronchial 
tree and nasal polyps in AIA and are important cell types in as-
pirin hypersensitivity of the airways.
27,28 Endobronchial aspirin 
challenge induced a decrease in the number of mast cells that 
stained for tryptase and an increase in the number of activated Allergy Asthma Immunol Res. 2010 January;2(1):48-54.  doi: 10.4168/aair.2010.2.1.48
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eosinophils, which reflects degranulation of these cell types 
and an early event associated with aspirin-sensitive reactions in 
AIA subjects.
29 Elevated levels of eotaxin and eotaxin-2 expres-
sion characterize tissue eosinophilia,
30 and these levels are 
changed after aspirin challenge.
31 In addition, both CYSLT1R 
and CYSLT2R are expressed on eosinophils, especially during 
exacerbation of asthma.
32 Leukotriene receptor antagonists are 
effective in treating AIA, because they inhibit the production of 
leukotrienes and the degree of eosinophilic inflammation in 
the airways.
33 Therefore, airway eosinophilia may be a critical 
marker for responsiveness. However, we did not examine the 
characteristics of airway inflammation in the present study.
In summary, the ability of a 12-week treatment with MLK to 
protect against aspirin-induced bronchospasm was evaluated 
in 46 adult patients with AIA. The protective effects were re-
markable, although 30% of the subjects still showed a positive 
response to aspirin challenge. The presence of aspirin hyper-
sensitivity and sinusitis among the clinical parameters and a 
greater response to aspirin challenge were associated with a 
poor response. These observations indicate that the increased 
responsiveness of the bronchial tree to aspirin challenge does 
not change in some AIA patients.
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